Levels of, and factors associated with, C-reactive protein in employees attending a company-sponsored cardiac screening program

Cardiology

Volumn 103, Issue 4, 2005, Pages 180-184

  Godefroi, Robert ^a   Klementowicz, Peter ^a   Pepler, Catherine ^a   Lewis, Barbara ^b   McDonough, Kenneth ^b   Goldberg, Robert J ^c  

^a BAE SYSTEMS   (United States)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

C reactive protein; Cardiovascular disease; Worksite screening program

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; EMPLOYEE; EXERCISE; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RISK FACTOR; SCREENING; SELF REPORT; TRIACYLGLYCEROL BLOOD LEVEL; WELLBEING;

ADULT; AGE FACTORS; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; EXERCISE; FEMALE; HEALTH PROMOTION; HEART DISEASES; HEART RATE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OBESITY; OCCUPATIONAL HEALTH; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES;

EID: 21044446124     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084591     Document Type: Article

References (17)

1. Ross R: Atherosclerosis: An inflammatory disease. N Engl J Med 1999;340:115-126.
2. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
3. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F: Markers of inflammation and cardiovascular disease: Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-979.
5. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
6. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 2000;321:199-204.
7. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, Elwood PC: C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584-1590.
8. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
9. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
10. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397.
11. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369.
12. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
13. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE investigators: Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001;286:64-70.
14. Albert MA, Glynn RJ, Ridker PM: Plasma concentration of C-reactive protein and the calculated Framingham coronary heart disease risk score. Circulation 2003;108:161-165.
15. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, D'Agostino RB, Franzblau C, Wilson PWF: Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. The Framingham Study. Stroke 2001;32:2575-2579.
16. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC: C-reactive protein and its relation to cardiovascular risk factors: A population based cross-sectional study. BMJ 1996;312:1061-1065.
17. Ridker PM: High-sensitivity C-reactive protein and cardiovascular risk: Rationale for screening and primary prevention. Am J Cardiol 2003;92(suppl):17K-22K.